TBILISI, MAY 8 2017 (The Conway Bulletin) — Georgia Healthcare Group reported a surge in revenue linked to its new pharmaceuticals business, underlining its position as one of the Central Asia/South Caucasus region’s best-performing stocks.
Shortly after announcing that revenue in the first quarter of the year had more than doubled to 186.6m lari ($76.5m) from 72.6m lari in 2016, Georgia Healthcare Group shares listed on the London Stock Exchange hit 370p. This was just shy of an all-time high of 379p reached earlier this year.
In a statement Georgian Healthcare, whose core business is running hospitals and health services, said that the addition of a pharmaceutical business had boosted its revenue.
“Our key focus during the first quarter of 2017 has been to ensure the successful integration of the newly-acquired Pharmadepot business,” it said in a statement.
Georgia Healthcare said it had a 29% share of the pharmaceuticals sector. It is Georgia’s largest healthcare provider, operating over 2,500 hospital beds, 23% of the market.
Georgia’s healthcare system has been revolutionized by the Georgian Dream government who introduced a variant of the Universal Healthcare model in 2013.
ENDS
Copyright ©The Conway Bulletin — all rights reserved
(News report from Issue No. 328, published on May 12 2017)